Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Rushnet Inc RSHN

RushNet, Inc. operates under the name HeliosDX. HeliosDX is a national clinical reference laboratory offering high-complexity urine drug testing (UDT), behavioral drug testing, allergy droplet cards, oral fluids, and infectious disease (PCR). The Company provides management services and insurance billing services principally to clinical reference laboratories. It provides PGX testing through Leo Partners. It provides oral fluid toxicology testing for a range of drugs. The Quantisal Collection Procedure makes taking the sample quick and easy. HeliosDX also offers a preliminary 10-panel plus adulteration detection screen, as well as confirmation testing via its comprehensive toxicology panel. Its subsidiaries include Chattahoochee Physicians Laboratory Services, LLC; doing business as HeliosDx and Grandeza Healthcare Consultants, LLC.


PINL:RSHN - Post by User

<< Previous
Bullboard Posts
Next >>
Post by AveragePennyon Aug 31, 2021 11:56am
83 Views
Post# 33787983

RSHN Remain as a Rushnet Subsidiary Along With Grandeza

RSHN Remain as a Rushnet Subsidiary Along With Grandeza

heliosDX, in the meantime, intends to close on the binding Letter of Intent it signed over the summer to acquire another sizable and profitable lab. Upon closing, heliosDX forecasts an annual combined revenue with the new lab of $16,000,000. After a full 12 months of combined operations, heliosDX forecasts revenues to be $20,000,000 to $25,000,000. In addition, we estimate our gross profit to remain above 80% of revenues, and our profit margin in the 25% to 30% range. Part of that margin maximization will be occasioned by using Grandeza for its billing purposes. Furthermore, heliosDX intends to pursue an additional 2 to 3 acquisitions we have previously targeted to reach its two-year objective of becoming a $50,000,000 annual revenue company. heliosDX has engaged counsel and will be pursuing listing on TSXV listing (the venture capital subsidiary of the Toronto Stock Exchange), and, to that end, is preparing two years of audited financial statements.

Grandeza, the newest subsidiary of RushNet, Inc, will continue to focus on building out its billing and coding platform. This is Grandeza's initial year of operations, albeit profitable. Nonetheless, Grandeza expects to exceed $1,600,000 in annual revenue. Grandeza has already derived more than $1,100,000 of revenues in eight months of operations this year and remains profitable despite its aggressive growth plans. Specifically, Grandeza intends to launch a healthcare employment placement service in late 2021/early 2022. This new division for Grandeza will be anchored by a future acquisition. It is Grandeza's objective, upon completion of its targeted acquisition to achieve annual revenues exceeding $3,000,000 in 2022.

https://www.accesswire.com/662131/heliosdx-to-remain-as-a-rushnet-subsidiary-along-with-grandeza-healthcare

<< Previous
Bullboard Posts
Next >>